1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Treatment-Resistant Depression (TRD)—Market Insights, Epidemiology, and Market Forecast-2028

Treatment-Resistant Depression (TRD)—Market Insights, Epidemiology, and Market Forecast-2028

  • September 2019
  • 207 pages
  • ID: 5816568
  • Format: PDF
  • By Delve Insight


Table of Contents

‘Treatment-Resistant Depression (TRD)—Market Insights, Epidemiology, and Market Forecast-2028’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Treatment-Resistant Depression in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Treatment-Resistant Depression from 2017 to 2028 segmented by seven major markets.
The phenomenon of Treatment-resistant depression (TRD) is described as the occurrence of an inadequate response after adequate treatment with antidepressant agents (in terms of dose, duration, and adherence). It has been broadly defined in the context of major depression disorder (MDD) (unipolar major depression), but alternative definitions for bipolar depression have also been suggested.
The European Union’s Committee for Human Proprietary Medicinal Products (CHMP) defines TRD as follows: ‘A patient is considered therapy-resistant (TRD) when consecutive treatments with two different antidepressant products, used for a sufficient length of time at an adequate dose with adequate affirmation of treatment adherence, fail to induce a clinically meaningful improvement.’

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2028

Treatment-Resistant Depression - Disease Understanding and Treatment Algorithm

The classification of TRD in stages has been recently proposed where increasing resistance is equated with an increased failure to respond to antidepressant strategies. The rationale behind this approach is the clinical impression that the greater the degree of treatment resistance, the lower the probability of response to any new treatment. This perspective has yet to be empirically tested, and it is important to keep in mind that all classifications of TRD are not diagnoses per se.
A relatively wide variety of treatment options for unipolar TRD are available, whilst the evidence is very scanty for bipolar TRD. TRD is associated with poor clinical, functional, and social outcomes. Several novel therapeutic options are currently being investigated as promising alternatives, targeting the neurotransmitter system outside of the standard monoamine hypothesis.

Treatment-Resistant Depression Epidemiology

The Treatment-Resistant Depression epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent cases, Gender-Specific Prevalence, and Age-Specific Prevalence) scenario of Treatment-Resistant Depression in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.
According to the analyst, the total prevalent cases of Treatment-Resistant Depression (TRD) in the 7MM was found to be 8,339,329 in 2017. The prevalence of Treatment-Resistant Depression in the 7MM is expected to increase during the study period of 2017–2028.
Treatment-Resistant Depression Drug Chapters
This segment of the Treatment-Resistant Depression report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the therapeutic market size of TRD in the US is mainly accounted for the management options consisting of pharmacologic treatment options and non-pharmacological therapies.
Pharmacologic treatment options include switching, combination and potentiation strategy among the commonly used antidepressant drugs. Most of the available antidepressants, such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), ?2-antagonists, Agomelatine, Tianeptine are used to treat TRD.
Spravato and Symbyax are the two FDA approved drugs specifically for the treatment of TRD. Other pharmacologic alternatives are also considered for those having an antidepressant action, such as in monotherapy: Bupropion, selective and reversible MAOIs, Quetiapine and in combination with a first-line antidepressant: Lithium, Lamotrigine and second-generation antipsychotics.
Non-pharmacological therapies include electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy involve majorly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT).
Detailed chapters of current therapies, such as Symbyax (olanzapine and fluoxetine hydrochloride) (Eli Lilly and Company), Spravato (Esketamine) (Johnson & Johnson), and emerging therapies, such as ALKS 5461 (Alkermes), AXS-05 (Axsome Therapeutics), Cariprazine (Allergan/Gedeon Richter’s), Pimavanserin (Acadia Pharmaceuticals), Seltorexant (J&J/ Minerva Neurosciences), Esketamine DPI (Celon Pharma), REL-1017 (Relmada Therapeutics), AV-101 (Vistagen therapeutics), and others have also been provided in the report.

Treatment-Resistant Depression Market Outlook

The Treatment-Resistant Depression market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
According to the analyst, the market for Treatment-Resistant Depression in 7MM was found to be approximately USD 3,698.34 Million in 2017.
Treatment-Resistant Depression market size in the United States accounted for 71% of the total market in 2017. The US led the market in 2017, followed by the EU5 and Japan, respectively. Due to the high prevalence of this disease in the region, the Treatment-Resistant Depression treatment market in the US is expected to dominate the market during the forecast period (2019–2028).
Treatment-Resistant Depression Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
The dynamics of Treatment-Resistant Depression market is anticipated to change in the coming years owing to the expected launch of emerging therapies, such as, AXS-05 (Axsome Therapeutics), ALKS-5461 (Alkermes), Esketamine Nasal Spray (Janssen Pharmaceuticals), Cariprazine (Allergan/ Gedeon Richter), Seltorexant (Minerva Neurosciences), Rapastinel (Naurex), Seltorexant (Minerva Neurosciences), Pimavanserin (Acadia Pharmaceuticals), and AV-101 (VistaGen Therapeutics), and others in the Treatment-Resistant Depression market by 2028.

Treatment-Resistant Depression Report Insights

• Patient Population of Treatment-Resistant Depression
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Treatment-Resistant Depression Report Key Strengths

• 10-Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Treatment-Resistant Depression Report Assessment

• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This report will help to develop Business Strategies by understanding the trends shaping and driving Treatment-Resistant Depression market
• Organize sales and marketing efforts by identifying the best opportunities for Treatment-Resistant Depression market
• To understand the future market competition in the Treatment-Resistant Depression market

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Treatment-Resistant Depression (TRD)—Epidemiology Forecast—2028

Treatment-Resistant Depression (TRD)—Epidemiology Forecast—2028

  • $ 3250
  • September 2019

‘Treatment-Resistant Depression (TRD)—Epidemiology Forecast—2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of Treatment-Resistant Depression ...

Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019

Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2019’; Glutamate Recepto ...

Global Pompe Disease Treatment Market Research Report Forecast to 2025

Global Pompe Disease Treatment Market Research Report Forecast to 2025

  • $ 4450
  • October 2019

Pompe Disease Treatment Market Research Report - Global Forecast till 2025Global Pompe Disease Treatment Market: Information by Type (Late-Onset Pompe Disease, Classic Infantile-Onset Pompe Disease, Non-Classic ...


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on